key: cord-0987284-7isd3pt4
authors: Sarfraz, Saliha; Saeed, Haleema
title: Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource‐limited setting amid the COVID‐19 pandemic
date: 2022-03-02
journal: Pediatr Blood Cancer
DOI: 10.1002/pbc.29595
sha: 625e083d625aa5b88f554a7b49ab6a9cc790c457
doc_id: 987284
cord_uid: 7isd3pt4

BACKGROUND: To assess feasibility and safety of outpatient administration of ifosfamide and etoposide (IE) for pediatric Ewing sarcoma (EWS) patients in a resource‐limited setting amid the COVID‐19 pandemic. MATERIALS AND METHODS: Retrospective study of patients with EWS who received outpatient IE from January 2020 until January 2021 at our institution. Ifosfamide 1800 mg/m(2) was given for 5 days with MESNA (2‐mercaptoethane sulfonate sodium) infusion and additional boluses before and after 9 hours of hydration. Patients >10 years of age with the ability to drink orally at home, no pre‐existing renal dysfunction or history of hematuria were included. They were monitored for hemorrhagic cystitis with a urine dipstick before, midway, and at end of infusion. A urine analysis was done 24 hours after the last dose of ifosfamide. RESULTS: Forty‐seven (100%) cycles were given as outpatient during the study period. Thirty‐five (74%) cycles were given on time, two (4%) cycles were delayed due to mucositis, two (4%) due to delayed count recovery, and eight (18%) due to unavailability of outpatient appointments. The median interval between these cycles was 15 days (range 14–44 days). No episode of hemorrhagic cystitis was reported. Urine analysis was not done at 24 hours for 27 (58%) cycles, so microscopic hematuria may have been missed. This outpatient protocol saved 32% (USD 299) per cycle in cost and 282 days of hospitalization. CONCLUSION: Outpatient administration of IE for pediatric patients with EWS is feasible, safe, and cost‐effective during the COVID‐19 pandemic.

Ewing sarcoma (EWS) is the second most common pediatric bone tumor. It is a highly aggressive cancer, with overall survival (OS) of 70% with nonmetastatic and ∼30% with metastatic disease. 1, 2 The treatment comprises neoadjuvant chemotherapy, followed by local control by surgery or radiotherapy. 3 The two weekly interval-compressed chemotherapy regimen of vincristine, doxorubicin, and cyclophosphamide (VDC) alternating with ifosfamide and etoposide (IE) is the standard of care for pediatric patients with EWS. The 5-year eventfree survival (EFS) in pediatric patients of nonmetastatic EWS has been improved from 65% to 73% by the use of an interval-compressed chemotherapy regimen that requires timely administration after every 2 weeks. 4, 5 The COVID-19 pandemic presents a global challenge to safe and effective pediatric cancer care, especially in low middle-income countries (LMIC). Around 90% of the world's pediatric cancer population belongs to LMIC. 6 The challenge is to provide pediatric cancer care due to the potential risk of significant delay in treatment and limited medical services, especially in LMIC, like Pakistan. 7 Delays in cancer treatment can lead to tumor progression and poorer outcomes. 8 So, there is an urgent need for safe and feasible adaptations to cancer treatment. 6 Ifosfamide is an alkylating agent and is activated by hepatic cytochrome P450 enzyme CYP3A4 into isophosphoramide mustard and toxic metabolite acrolein. Acrolein is associated with urothelial toxicity leading to hemorrhagic cystitis. This toxicity can be prevented by infusion of thiol compound 2-mercaptoethane sulfonate sodium (MESNA), followed by hyperhydration for 24 hours after ifosfamide administration. 3 MESNA provides uro-protection by binding with acrolein, preventing damage to bladder epithelium. 9 This requires inpatient admission for 6 days, and places a significant admission burden on hospitals, and causes delays in treatment when inpatient hospital beds are already limited, especially during the COVID-19 pandemic.

So, an altered regimen needs to be followed to replace long treatment visits with shorter hospital visits. 10 Elshahoubi et al. 2 and Maezza et al. 3 have demonstrated that IE can be administered in the outpatient setting without any increase in toxicity. However, no significant local data regarding the feasibility of outpatient administration of IE in pediatric EWS in a resourcelimited country like Pakistan is available. So, based on previously published studies, an institutional protocol for safe outpatient administration of 1800 mg/m 2 of ifosfamide for 5 days with MESNA hydration was developed to reduce days of inpatient hospitalization and to ensure safe and timely administration of IE for pediatric patients with EWS. We conducted this study to assess the feasibility and safety of outpatient administration of IE for pediatric patients with EWS in a resource-limited setting amid the COVID -19 pandemic. They were admitted if persistent emesis or hematuria developed at any time.

Data were analyzed using a Statistical Package for Social Sciences (SPSS) version 20. Age was presented as mean and standard deviation. Categorical data like the outcome in terms of the timely administration of chemotherapy, the incidence of hemorrhagic cystitis, reduction of cost of administration of chemotherapy, and reduction in days of hospitalization were presented as frequencies and percentages.

In our study, a total of 20 patients were studied, the mean age was 13.9 ± 2.12 years. Twelve (60%) were males and eight (40%) were females. The male to female ratio was 1.5:1. Total 47 cycles were given as outpatient during the study period.

Thirty-five (74%) cycles were given on time, two (4%) cycles were delayed due to mucositis, two (4%) due to delayed count recovery, and eight (18%) due to lack of availability of outpatient appointments.

The median interval between the chemotherapy cycles was 15 days 

There were no documented episodes of hemorrhagic cystitis. Urine analysis was not done after 24 hours of the last dose of ifosfamide for 27 (58%) cycles, so microscopic hematuria may have been missed.

However, none of the patients developed gross hematuria. 

The protocol used in our study for safe outpatient administration of IE 3 These studies showed that ifosfamide could be safely administered to outpatients, replacing the 24 hours prolonged MESNA hyperhydration with 9 hours long simplified hyperhydration. Thus, resulting in shorter hospital stays and consequently lower costs. 3 The Children's Oncology Group (COG) study showed that the compressed chemotherapy regimen (AEWS0031) improved 5-year EFS in pediatric patients of nonmetastatic ESW from 65% to 73% in contrast to three weekly standard chemotherapy regimen. The prognosis was improved by timely two weekly interval-compressed chemotherapy, followed by granulocyte colony-stimulating factor for accelerated neutrophilic and platelet count recovery. 5 It required inpatient admission for 6 days after every 2 weeks and led to a significantly high admission burden on resource-limited countries. Delay in chemotherapy administration may lead to tumor progression and worse outcomes. It poses a dilemma for LMICs where health care resources are limited.

Pediatric cancer care has been considerably affected by the COVID-19 pandemic. 11 The major concern for cancer patients is the inability to receive necessary cancer treatment on time. 12 It has led to an increased burden on inpatient hospital beds and significant delays in cancer treatment, resulting in poorer disease outcomes and exhaustion of health care services. 10 Edge R showed that 42% of cancer patients and survivors reported some level of disruption to their cancer treatment. 11 The limited human and medical resources in the COVID-19 crisis emphasize the need for prioritization of beneficial treatments. 13 pandemic. 14 So, the cancer treatment needs to be delivered on time with safe and feasible adaptive measures. 12 We observed that IE can be given with 100% success in the outpatient department in pediatric patients with EWS in a resource-limited setting and inpatient admissions can be averted and these beds can be saved for the COVID-19 patients.

Low-income and middle-income countries have predominantly large younger populations and fragile health care system. 15 Therefore,

LMICs have a larger burden of cancer-related deaths than high-income countries (HICs). 16 In HICs, 80% of pediatric cancer patients are treated successfully. 17 In contrast, about 70% of cancer deaths occur in LMICs. 18 The survival for EWS in children in LMICs falls behind HICs due to the nonavailability of timely, effective, and affordable treatment. 19 The increase in cancer burden in LMICs poses a threat to already frail health care and economic infrastructure. Despite the availability of effective chemotherapy, cost-effectiveness is of utmost concern. 20 The two weekly interval-compressed inpatient chemotherapy regimen in pediatric patients with EWS places a significant burden on cancer care services in LMIC. So, this outpatient IE administration protocol can be used routinely in LMIC like Pakistan, where inpatient beds and medical finances are limited.

The limitation to our study was that it was a retrospective study conducted on a small number of patients. The analysis of the quality of life of patients who received IE as an outpatient and long-term toxicities of ifosfamide are the domains that need further exploration.

Outpatient administration of IE for pediatric patients with EWS is feasible, safe, and cost-effective, with a reduction in the cost of chemother-apy and days of hospitalization. This was particularly useful in the timely administration of chemotherapy during the COVID-19 pandemic when inpatient beds were limited.

We thank the doctors and nursing team of department of Pediatric

Centre Lahore for its encouragement and support for the research article

The authors declare that there is no conflict of interest.

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Saliha Sarfraz https://orcid.org/0000-0003-2130-4428

Transcriptional programs define intratumoral heterogeneity of Ewing sarcoma at single-cell resolution

Safety and cost-effectiveness of outpatient administration of high-dose chemotherapy in children with Ewing sarcoma

Full-dose ifosfamide can be safely administered to outpatients. Pediatr Blood Cancer

Feasibility of compressed chemotherapy pediatric Ewing sarcoma regimen in Pakistan

Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group [published correction appears in

The COVID-19 pandemic: a rapid global response for children with cancer from SIOP

Acute morbidity and mortality analysis of COVID-19 in children receiving cancer treatment

A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID-19) pandemic: an international collaborative group

Continuously improving ifosfamide/mesna: a winning combination

Treatment delays in oncology patients during COVID-19 pandemic: a perspective

Cancer care disruption and reorganisation during the COVID-19 pandemic in Australia: a patient, carer and healthcare worker perspective

Sarcoma European and Latin American Network (SELNET) recommendations on prioritization in sarcoma care during the COVID-19 pandemic

Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic

Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients' perspective

Paediatric cancer in low-income and middle-income countries

Global cancer incidence and mortality rates and trends-an update

The International Bank for Reconstruction and Development/The World Bank

How should low-and middle-income countries motivate equity in cancer prevention and control?

Challenges in the management of localized Ewing sarcoma in a developing country

Cancer control in low-and middle-income countries: is it time to consider screening?

Feasibility and safety of outpatient administration of ifosfamide and etoposide for pediatric patients with Ewing sarcoma in a resource-limited setting amid the COVID-19 pandemic